$JBIO News

Last published 13h ago

13h agoJBIOJade Biosciences, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
13h agoJBIOJade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireSAN FRANCISCO and VANCOUVER, British Columbia, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the third quarter ending September 30, 2026, and provided a corporate update.
1w agoJBIOJade Biosciences to Participate in Upcoming ConferencesGlobeNewswireSAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on
3w agoJBIOJade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026GlobeNewswireEVERGREEN Phase 3 Trial-in-Progress poster presents planned study design of JADE101 in IgA nephropathy; initiation now expected in the fourth quarter of 2026JUNIPER Phase 2 Trial-in-Progress poster highlights ongoing
1mo agoJBIOJADE301 Webcast - JADE BIOSCIENCES INCEarnings Call TranscriptsGood morning, and welcome to the Jade Biosciences Jade 301 conference call and webcast. Please note that this call is being recorded and will be available for replay on jadebiosciencias.com. At this time, all participant
1mo agoJBIOSTIFEL 2026 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM - JADE BIOSCIENCES INCEarnings Call TranscriptsHey, everyone. We're back. Really happy to have the Jade Biosciences team here with us for the next Fireside. Tom Froelich, CEO, Andrew King, President of R&D, CSO, IGAN extraordinaire. So maybe I'll kick it over to Tom
2mo agoJBIOJade Biosciences to Participate in Upcoming ConferencesGlobeNewswireSAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on
3mo agoJBIOJade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireAnnounced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy Phase 2 JADE101 clinical trial in IgA
4mo agoJBIOJade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of DirectorsGlobeNewswireSAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the "Company" or "Jade") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on
5mo agoJBIOJade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireSAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing
5mo agoJBIOJade Biosciences Announces Pricing of Public Offering of Common StockGlobeNewswireSAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing
5mo agoJBIOJade Biosciences Announces Proposed Underwritten Public OfferingGlobeNewswireSAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing
5mo agoJBIOJade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA NephropathyGlobeNewswire~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect observed to be
5mo agoJBIOJade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA NephropathyGlobeNewswireSAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the "Company" or "Jade") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class
5mo agoJBIOJade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal AntibodyGlobeNewswireInterim Phase 1 data in rheumatoid arthritis expected in 2027 are anticipated to inform indication prioritization across multiple potential autoimmune indications supported by BAFF-R biology JADE201 preclinical data
5mo agoJBIOJade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA NephropathyGlobeNewswireInterim Phase 2 JADE101 data are expected in 2027 SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the "Company" or "Jade") (NASDAQ:JBIO), a clinical-stage
6mo agoJBIOJade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireInterim biomarker-rich Phase 1 data for JADE101 to be featured in an oral session at the 63rd European Renal Association Congress Phase 2 trial of JADE101 in IgA nephropathy patients expected to begin in the second
6mo agoJBIOJade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing
6mo agoJBIOJade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical OfficerGlobeNewswireSAN FRANCISCO and VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing
8mo agoJBIOJade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswireJADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated in 2027JADE201,
9mo agoJBIOJade Biosciences to Participate in Upcoming ConferencesGlobeNewswireSAN FRANCISCO and VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade"), (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune
10mo agoJBIOJade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireJADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin mid-2026; preliminary
11mo agoJBIOJade Biosciences Announces $45 Million Private PlacementGlobeNewswireSAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing
1y agoJBIOJade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswirePresented favorable preclinical safety data for JADE101 and a translational analysis of APRIL mediated biomarker responses at the American Society of Nephrology Kidney Week 2025, reinforcing its potential as a
1y agoJBIOJade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025GlobeNewswireSAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing
1y agoJBIOJade Biosciences to Participate in Upcoming ConferencesGlobeNewswireSAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade"), (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune
1y agoJBIOJade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025GlobeNewswirePresentations to highlight JADE101's preclinical safety profile and translational framework guiding its clinical development in IgA nephropathyJADE101 is an investigational, potentially best-in-class disease-modifying
1y agoJBIOJade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune DiseasesGlobeNewswireJADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell depletion with less
1y agoJBIOJade Biosciences Announces $135 Million Private PlacementGlobeNewswireSAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing
1y agoJBIOJade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA NephropathyGlobeNewswireSelective APRIL inhibition has shown disease-modifying potential in IgAN patient clinical trialsJADE101 has shown ultra-high binding affinity and a differentiated pharmacokinetic and pharmacodynamic profile
1y agoJBIOJade Biosciences to Participate in Upcoming ConferencesGlobeNewswireSAN FRANCISCO and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade"), (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune
1y agoJBIOJade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswirePresented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal antibody for IgA nephropathy Phase 1 healthy-volunteer study of
1y agoJBIOJade Biosciences Appoints Brad Dahms as Chief Financial OfficerGlobeNewswireSAN FRANCISCO and VANCOUVER, British Columbia, July 01, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade") (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune
1y agoJBIOJade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA NephropathyGlobeNewswirePreclinical data highlighted JADE101's femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppression In non-human primates, JADE101 showed a
1y agoJBIOJade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association CongressGlobeNewswireSAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade") (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune
1y agoJBIOJade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireCompleted reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to enter the clinic in
1y agoJBIOJade Biosciences to Participate in the 2025 Jefferies Global Healthcare ConferenceGlobeNewswireSAN FRANCISCO and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade"), (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune